Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 421

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 421
---
 said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their and his or her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on February 28, 2025:

    Signature
     
    Title

    /s/ Douglas S. Ingram
     
    President, Chief Executive Officer and Director (Principal Executive Officer)

    Douglas S. Ingram

    /s/ Ian M. Estepan
     
    Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)

    Ian M. Estepan

    /s/ M. Kathleen Behrens
     
    Chairwoman of the Board

    M. Kathleen Behrens, Ph.D.

    /s/ Richard Barry
     
    Director

    Richard Barry

    /s/ Deirdre Connelly
     
    Director

    Deirdre Connelly

    /s/ Kathryn Boor
     
    Director

    Kathryn J. Boor, Ph.D.

    /s/ Michael A. Chambers
     
    Director

    Michael A. Chambers

    /s/ Stephen L. Mayo
     
    Director

    Stephen L. Mayo, Ph.D.

    /s/ Claude Nicaise
     
    Director

    Claude Nicaise, MD

    /s/ Hans Wigzell
     
    Director

    Hans Wigzell, M.D., Ph.D.

-92-

SAREPTA THERAPEUTICS, INC.

CONSOLIDATED FINANCIAL STATEMENTS

    PageNumber

    Report of Independent Registered Public Accounting Firm (KPMG LLP, Boston, MA, Auditor Firm ID: 185)
     
    F-2

    Consolidated Balance Sheets
     
    F-4

    Consolidated Statements of Comprehensive Income (Loss)
     
    F-5

    Consolidated Statements of Stockholders’ Equity
     
    F-6

    Consolidated Statements of Cash Flows
     
    F-7

    Notes to Consolidated Financial Statements
     
    F-8

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

Sare